Corporation (NASDAQ: GENZ) today recognized International Rare
Disease Day with the launch of a new program, the Genzyme Patient
Advocacy Leadership Awards (PAL Awards). A global grant program, the
Genzyme PAL Awards will support non-profit organizations that work on
behalf of patients living with lysosomal storage disorders (LSDs), a
group of rare, inherited disorders that cause progressive and
debilitating health problems. A total of $50,000 will be awarded through
a competitive application process to organizations that seek funding for
new initiatives that support the LSD patient community.
?For 30 years, Genzyme has been supporting patients through pioneering
new treatments, free drug programs and through ongoing partnerships with
patient organizations that serve the LSD patient community,? said
Genzyme's Director of Patient Advocacy, Jamie Manganello. ?International
Rare Disease Day is a great moment to launch the PAL Awards to
commemorate the progress that has been made in partnership with the
patient community, and as a reminder of our commitment to the work that
is still ahead for us on behalf of patients and families affected by
Organizations may apply for a Genzyme PAL Award for programs that
support disease awareness, advocacy on behalf of patient communities,
patient education and patient care, support and communication networks.
This grant program is supplemental to Genzyme's existing grants program
and will not replace the contributions made locally each year to support
advocacy groups. Proposals will be reviewed by an external review
committee. Applications must be received by June 15, 2011, and the award
recipients will be announced by July 31, 2011. For more information on
the Genzyme PAL Awards program, or to apply for a grant, please visit www.genzymeadvocacyawards.com.
February 28, 2011 marks the fourth International Rare Disease Day,
created by the patient organization EURORDIS and involving rare disease
organizations globally. Genzyme is proud to have been a partner each
year for International Rare Disease Day, and has organized events at
Genzyme locations around this year's theme, ?Rare but Equal.? These
events include presentations by patients with rare diseases at Genzyme
offices, participation in a public event at the Massachusetts State
House and today's launch of the Genzyme PAL Awards.
One of the world's leading biotechnology companies, Genzyme is dedicated
to making a major positive impact on the lives of people with serious
diseases. Since 1981, the company has grown from a small start-up to a
diversified enterprise with approximately 10,000 employees in locations
spanning the globe. Genzyme this month announced an agreement to be
acquired by sanofi-aventis, and the transaction is expected to close
early in the second quarter of this year.
With many established products and services helping patients in 100
countries, Genzyme is a leader in the effort to develop and apply the
most advanced technologies in the life sciences. The company's products
and services are focused on rare inherited disorders, kidney disease,
orthopaedics, cancer, transplant, and immune disease. Genzyme's
commitment to innovation continues today with a substantial development
program focused on these fields, as well as cardiovascular disease,
neurodegenerative diseases, and other areas of unmet medical need.
Genzyme's press releases and other company information are available at www.genzyme.com
and by calling Genzyme's investor information line at 1-800-905-4369
within the United States or 1-678-999-4572 outside the United States.
Genzyme has filed with the Securities and Exchange Commission a
Solicitation/Recommendation Statement on Schedule 14D-9 relating to the
tender offer by Sanofi-Aventis. Genzyme shareholders are advised to read
the company's Solicitation/Recommendation Statement on Schedule 14D-9
because it contains important information. Shareholders may obtain a
free copy of the Solicitation/Recommendation Statement on Schedule
14D-9, as well as any other documents filed by Genzyme in connection
with the tender offer, free of charge at the SEC's website at http://www.sec.gov.
In addition, investors can obtain free copies of these documents from
Genzyme by directing a request to Genzyme at 500 Kendall Street,
Cambridge, MA 02142, Attention: Shareholder Relations Department, or by
calling 617-252-7500 and asking for the Shareholder Relations Department.
Patrick Flanigan, 617-768-6563